-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftriaxone in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftriaxone in Gram-Negative Bacterial Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftriaxone in Gram-Negative Bacterial Infections Drug Details: Ceftriaxone is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftriaxone in Gram-Positive Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftriaxone in Gram-Positive Bacterial Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftriaxone in Gram-Positive Bacterial Infections Drug Details: Ceftriaxone is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crovalimab in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crovalimab in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crovalimab in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Crovalimab (Piasky) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furosemide in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furosemide in Congestive Heart Failure (Heart Failure) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furosemide in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furosemide in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Malignant Pleural Mesothelioma Drug Details: Lenvatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RMC-6291 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RMC-6291 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RMC-6291 in Colorectal Cancer Drug Details:RMC-6291 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Furosemide in Congestive Heart Failure (Heart Failure) Drug Details:Furosemide (Furoscix) is a sulfamoylanthranilic acid derivative, acts...
-
Company Profile
scPharmaceuticals Inc – Company Profile
ScPharmaceuticals Inc (scPharmaceuticals) is a clinical-stage pharmaceutical company. The company’s pipeline products include subcutaneous formulations of furosemide, ceftriaxone and carbapenem. Its product ceftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. The company’s carbapenems are antibiotics used intravenously for the treatment of infections caused by gram-negative organisms. It also provides clinical trial services. The company operates in the US. scPharmaceuticals is headquartered in Burlington, Massachusetts, the US.
Add to Basket -
Product Insights
Net Present Value Model: Furoscix
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Furoscix Drug Details Furosemide (Furoscix) is...